Capital World Investors
APGE icon

Capital World Investors’s Apogee Therapeutics APGE Stock Holding History

Capital World Investors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-348,674
Closed -$29.3M – 640
2026
Q1 		$29.3M Buy
348,674
+221,056
+173% +$16.1M ﹤0.01% 510
2025
Q4 		$9.63M Hold
127,618
– – ﹤0.01% 508
2025
Q3 		$5.07M Sell
127,618
-66,277
-34% -$2.53M ﹤0.01% 516
2025
Q2 		$8.42M Hold
193,895
– – ﹤0.01% 506
2025
Q1 		$7.24M Sell
193,895
-11,205
-5% -$433K ﹤0.01% 495
2024
Q4 		$9.29M Buy
+205,100
New +$10.5M ﹤0.01% 482

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Capital World Investors's APGE Position: Q2 2026 in Review

Capital World Investors sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 348,674 shares — an estimated $29.3M sold.

Capital World Investors first reported a position in APGE in Q4 2024 and held it in 6 quarters. The position peaked at $29.3M in Q1 2026. 173 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Capital World Investors reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Capital World Investors sold 348,674 Apogee Therapeutics shares in Q2 2026, an estimated $29.3M.
  • Capital World Investors first reported a position in Apogee Therapeutics in Q4 2024 and held it in 6 quarters.
  • Capital World Investors's Apogee Therapeutics position peaked at $29.3M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.